Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct
Launched by NATIONAL UNIVERSITY OF MALAYSIA · Oct 26, 2011
Trial Information
Current as of May 16, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Experiences stroke onset within 2 weeks to 2 months
- • NIHSS score of \>10-35
- • Never received or failed thrombolysis
- • Evidence of unilateral middle cerebral artery infarct on brain MRI
- Exclusion Criteria:
- • Medically unfit (eg. those are unstable haemodynamically despite treatment, with worsening conscious level and with other serious medical co-morbidity)
- • Evidence of any tumor or other space-occupying lesion on brain MRI
- • Evidence of hemorrhagic stroke on brain CT or MRI
- • Experiences transient ischemic attack or lacunar infarct
- • Has any acute or chronic infections such as Hepatitis B, Hepatitis C and HIV
- • Is diagnosed with concurrent malignancy or primary hematological disorders
- • Renal impairment indicated with serum creatinine greater than 200 umol/l or creatinine clearance less than 30 ml/min
- • Liver impairment indicated with serum aspartate transaminase and serum alanine transaminase greater than 4 times upper limit of the normal range
- • Any contraindication to stem cell transplantation or bone marrow biopsy
- • Any co-morbidity which will compromise the ability to obtain adequate stem cells (eg. chronic debilitating diseases, frail patients and patients with known osteoporosis)
- • Any contraindication to brain MRI (eg. metal implants, pacemaker, joint implants and ocular implants)
About National University Of Malaysia
The National University of Malaysia (Universiti Kebangsaan Malaysia, UKM) is a prestigious institution dedicated to advancing medical research and clinical trials that contribute significantly to the fields of healthcare and biomedical sciences. As a leading academic and research university, UKM is committed to fostering innovation and excellence in clinical research, promoting collaboration among multidisciplinary teams, and enhancing the quality of patient care. The university's robust infrastructure and experienced research faculty facilitate rigorous clinical trials aimed at addressing critical health challenges, thereby improving health outcomes both locally and globally. Through its dedication to ethical research practices and adherence to regulatory standards, UKM strives to enhance the understanding of diseases and develop effective interventions that benefit society.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kuala Lumpur, , Malaysia
Patients applied
Trial Officials
Norlinah Mohamed Ibrahim, MD
Principal Investigator
UKM Medical Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials